| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/07/2023 | 344.37% | Cantor Fitzgerald | → $1.3 | Reiterates | Neutral → Neutral |
| 06/06/2023 | — | HC Wainwright & Co. | Reiterates | → Neutral | |
| 04/04/2023 | — | Maxim Group | Downgrades | Buy → Hold | |
| 04/04/2023 | — | Brookline Capital | Downgrades | Buy → Hold | |
| 04/04/2023 | 344.37% | Cantor Fitzgerald | $4 → $1.3 | Maintains | Overweight |
| 04/04/2023 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 04/04/2023 | — | Oppenheimer | Downgrades | Outperform → Perform | |
| 03/22/2023 | 2976.4% | Oppenheimer | $14 → $9 | Maintains | Outperform |
| 03/14/2023 | 2292.75% | HC Wainwright & Co. | → $7 | Reiterates | → Buy |
| 12/22/2022 | 1267.29% | Cantor Fitzgerald | → $4 | Initiates Coverage On | → Overweight |
| 08/10/2022 | 2292.75% | HC Wainwright & Co. | $8 → $7 | Maintains | Buy |
| 05/10/2022 | 1096.38% | Maxim Group | → $3.5 | Initiates Coverage On | → Buy |
| 02/24/2022 | 1609.11% | BTIG | → $5 | Initiates Coverage On | → Buy |
| 04/07/2021 | 4685.51% | Oppenheimer | → $14 | Initiates Coverage On | → Outperform |
| 03/30/2021 | 5369.15% | Brookline Capital | → $16 | Initiates Coverage On | → Buy |
| 03/12/2021 | 2976.4% | HC Wainwright & Co. | $8 → $9 | Maintains | Buy |
What is the target price for Oncternal Therapeutics (ONCT)?
The latest price target for Oncternal Therapeutics (NASDAQ: ONCT) was reported by Cantor Fitzgerald on September 7, 2023. The analyst firm set a price target for $1.30 expecting ONCT to rise to within 12 months (a possible 344.37% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Oncternal Therapeutics (ONCT)?
The latest analyst rating for Oncternal Therapeutics (NASDAQ: ONCT) was provided by Cantor Fitzgerald, and Oncternal Therapeutics reiterated their neutral rating.
When is the next analyst rating going to be posted or updated for Oncternal Therapeutics (ONCT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Oncternal Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Oncternal Therapeutics was filed on September 7, 2023 so you should expect the next rating to be made available sometime around September 7, 2024.
Is the Analyst Rating Oncternal Therapeutics (ONCT) correct?
While ratings are subjective and will change, the latest Oncternal Therapeutics (ONCT) rating was a reiterated with a price target of $0.00 to $1.30. The current price Oncternal Therapeutics (ONCT) is trading at is $0.29, which is within the analyst's predicted range.